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Purpose: Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-
regulation of the three vital signaling pathways: mitogen activated protein kinase, phos-
phoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription
pathways. Blocking HER1/EGFR has a limited anticancer effect due to either secondary
mutation e.g., T790M or by-pass signaling of other HER members. The emergence of an
anti-panHER approach to blockade of these pathways as a cancer treatment may provide a
solution to this resistance. This review aimed to provide an overview of the HER signaling
pathways and their involvement in tumor progression and examine the current progress in
panHER inhibition.
Methods: Recent literature associated with HER signaling pathways and panHER inhibi-
tion was reviewed through PubMed and Medline database, followed by critical comparison
and analysis.
Results: Pre-clinical studies and clinical trials of panHER inhibitors show promising results,
and the potential to improve patient outcomes in solid cancers.
Conclusion: The use of panHER inhibitors in cancers with HER-family hyper-activation,
such as other epithelial cancers and sarcoma, is a new direction to research and has
potential in clinical cancer therapy in the future.
Keywords: targeted therapy, panHER inhibitors, drug resistance, HER signaling pathways, EGFR
INTRODUCTION
Cancer continues to pose a great problem and burden on soci-
ety despite new treatment options. In Australia, it is the most
common cause of death and the leading cause of burden of dis-
ease (19%) (1). In 2007, the incidence of cancer was 485 cases per
100,000 people and the death rate was 176 per 100,000 people. The
most common cancers are prostate cancer, bowel cancer, breast
cancer, melanoma of skin, and lung cancer. While surgery, radio-
therapy, and chemotherapy have led to major improvements in
patient prognosis, newer treatments are needed to more effectively
manage this disease in its advanced stage.
Over-expression of the human epidermal growth factor recep-
tor (EGFR/HER1) pathway is a feature of many cancers and a
potential therapeutic target. Early research suggested that block-
ing EGFR/HER1 by its specific inhibitor may have activity in some
cancers through tyrosine kinase signaling inhibition (2). However,
such a blockade can induce secondary mutation (T790M) (3)
Abbreviations: EGFR, the epidermal growth factor receptor; GRB2, growth-factor-
receptor bound-2; HER, the human epidermal growth factor receptor; JAK/STAT,
the Janus kinas/signal transducer and activator of transcription; MAPK, the mito-
gen activated protein kinase; MEK, mitogen activated protein kinase kinase; MTD,
maximum tolerated dose; mTOR, mammalian target of rapamycin; NSCLC, non-
small cell lung cancer; PI3K/AKT, the phosphoinositide 3-kinase/AKT; PKB, protein
kinase B; SHC, Src-homology-2-containing; TKD, tyrosine kinase domain; TKIs,
tyrosine kinase inhibitors.
and, in addition, has no impact on the other tyrosine kinase
receptors within the HER-family (HER2/4) (4). This potentially
allows by-pass signaling pathways to remain active; a prime
example being the Janus kinase/signal transducer and activator
of transcription (JAK/STAT) pathway, which is normally regu-
lated via HER members (5). Other resistance mechanism like
c-MET amplification/over-expression may also weaken the effect
of HER-family inhibition (6, 7).
Understanding the mechanism of each HER-family member,
their signaling pathways and interactions among them will have
a great impact on designing treatment approaches to conquer
the resistance of EGFR/HER1 targeted therapy. This review has
endeavored to provide an overview of the HER signaling pathways
and their involvement in tumor progression and to examine the
current progress in HER-family inhibition.
HER-FAMILY MEMBERS AND THEIR SIGNALING PATHWAYS
The HER signaling pathways are normally involved in regulation
of cell growth and survival as well as adhesion, migration, differ-
entiation, and other cellular responses. An understanding of these
pathways is vital in appreciating the action of panHER inhibitors
and anti-HER member antibodies. There are four members of
the family, including EGFR/HER1, HER2, HER3, and HER4 (also
called erbB-1, erbB-2, erbB-3, and erbB-4, respectively).
Hyper-activation of these receptors culminates with downstream
up-regulation of the mitogen activated protein kinase (MAPK),
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phosphoinositide 3-kinase/AKT (PI3K/AKT), and JAK/STAT
pathways (8). In cancer, these pathways are linked to many cellular
processes including tumor progression, angiogenesis, metastatic
spread, and inhibition of apoptosis (9). This hyper-activation may
be due to over-expression of HER ligands, receptors or sustained
activation of receptors, as summarized in Table 1.
The HER receptors are composed of a large extra-cellular
ligand-binding domain, which has four subdomains (I–IV),
followed by a transmembrane domain, a small intracellular
juxtamembrane domain preceding the kinase domain, and a
C-terminal tail, on which the docking sites for phosphotyrosine-
binding effector molecules are found (10). These four receptors
form homo-dimers and hetero-dimers, which are associated with
instigation of different downstream pathways. Emerging targeted
treatment has focused on inhibition of these HER receptors via
either external monoclonal antibodies (mAb) or small molecule
tyrosine kinase inhibitors (TKIs). Figure 1 presents a simplified
summary of the HER signaling pathways.
EGFR/HER1 PATHWAYS
EGFR/HER1 has been shown to be involved in proliferation
and differentiation of epithelial tissues of the skin, lung, pan-
creas, and gastrointestinal tract (13). Binding of ligands to EGFR
leads to auto-phosphorylation of critical tyrosine residues, which
serve as attachment sites for various cellular-docking proteins
to activate signaling cascades and affect gene transcription (14).
Cellular-docking proteins include growth factor receptor bound-2
(GRB2) and Src-homology-2-containing (SHC), both concerned
with recruitment of ras and activation of the MAPK cascades (15).
Furthermore, MAPK specifically phosphorylates a serine near the
C-terminus of most STATs,dramatically enhancing transcriptional
activation by STAT (11).
EGFR/HER1 has highly specific recognition sites, and is unable
to recruit PI3K (12). As such, EGFR/HER1 cannot directly activate
Table 1 | HER ligands and receptors.
Receptor
homodimer/
heterodimer
Ligands Over-expression
associated malignancies
EGFR (HER1) EGF, TGF-α, AR, HB-EGF,
EPG, EPR, BTC
NSCLC, breast, glioma, head
and neck, bladder, kidney, soft
tissue sarcoma
HER2/HER3 EPR, NRG1-α, NRG2-β Breast
HER3 NRG1-β, NRG2-β Breast, colon, gastric, prostate,
other carcinomas, soft tissue
sarcoma
HER4 HB-EGF, BTC, EPR,
NRG1-β, NRG2-β, NRG4
Childhood medullo-blastoma
HER2/HER4 EGF, TGF-α, HB-EGF, EPR,
BTC, NRG2-α, NRG3
EGF, epidermal growth factor;TGF, transforming growth factor; AR, amphiregulin;
HB-EGF, heparin binding epidermal growth factor; EPG, epigen; EPR, epiregulin;
BTC, betacellulin; NRG, neuregulin.
the PI3K/AKT/protein kinase B (PKB) pathway, but it converges
with the ras/MAPK pathway as well as via ras to the ras/PI3K/
AKT/PKB pathway (10).
HER2 PATHWAYS
HER2 only functions when partnered with either one of the other
three type I receptor tyrosine kinase family members (HER1,
HER3, or HER4) or type II receptor tyrosine kinase family
members (IR or IGF-IR) (16–20). It is a current understanding
that HER2 as an orphan receptor cannot directly bind any lig-
ands. Rather, it dimerizes with ligand-bound receptors. However,
when expressed as a heterodimer, the combination-receptor shows
higher affinity and broader specificity for ligands than other het-
erodimer couples (21). These advantages are due to slower growth
factor dissociation, as well as slow endocytosis of HER2 contain-
ing hetero-dimers. Hence, HER2-associated hetero-dimers show
a strong proliferative potential as there is simultaneous and pro-
longed recruitment of multiple signaling pathways including the
JAK/STAT pathway (22). Several types of cancer are associated with
HER2 over-expression, being most thoroughly studied in breast
cancer where there is gene amplification in 15–30% of invasive
ductal carcinomas (23).
Trastuzumab is a humanized mAb directed against the extra-
cellular domain of the HER2 receptor. It has been shown to
have major clinical benefits when used in HER2 overexpress-
ing breast cancer, which otherwise carries a very poor prognosis
(24). The mechanism of action is complex, ultimately provid-
ing antibody-dependent cellular cytotoxicity (ADCC) against cells
FIGURE 1 | Signal transduction by HER-family. This figure summarizes
the interplay between three pathways: MAPK, P13K/AKT, and JAK/STAT.
MAPK dramatically enhances transcriptional activation by STAT (11).
EGFR/HER1 cannot directly activate the P13K/AKT pathway (12), but it
couples to the ras/MAPK pathway as well as to the ras/PI3K/AKT pathway
(10). This interplay of pathways forms the source of by-pass resistance to
EGFR TKIs. TKD, tyrosine kinase domain; MEK, mitogen activated protein
kinase kinase; MAPK, mitogen activated protein kinase; PI3K,
phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; JAK,
janus kinase; STAT, signal transducer and activator of transcription.
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overexpressing HER2 as well as down-regulation of signaling
pathways including MAPK and AKT (18).
In malignant tumors, constitutively activated HER2 and
EGFR/HER1 not surprisingly stimulate many of the same intra-
cellular signaling proteins and pathways as wild-type receptors,
such as the MAPK, PI3K/AKT/mTOR pathway, Src kinase, and
STAT transcription factors (25). However, differences arise due to
impairment of the usual negative regulatory loops functioning in
normal cells (26). Without such negative feedback, cells are able
to proliferate in an uncontrolled manner.
HER3 PATHWAYS
HER3 is another non-autonomous receptor, which forms func-
tional hetero-dimers with the other members of the HER-
family. It has defective kinase activity and only acquires signal-
ing potential, that is, tyrosine phosphorylation, when dimerized
with another receptor. Upon heterodimerization, the cytoplasmic
domain of HER3 undergoes aforementioned tyrosine phosphory-
lation allowing recruitment of PI3K as well as SHC, although not
GRB2 (27). Additionally, upon heterodimerization, HER3 strongly
promotes PI3K activation; especially when binding to its’ preferred
partner HER2 (28). Activation of PI3K pathway is closely associ-
ated with survival signals allowing avoidance of apoptosis (29).
HER3 is expressed in many cancers, although there is no evi-
dence to suggest gene amplification and over-expression (30). In
malignancies such as ovarian cancer where HER3 is frequently
expressed (53.4%), expression has been associated with a shorter
survival time (3.31 vs. 1.8 years median survival time: low HER3
expression and HER3 over-expression, respectively) (31).
HER4 PATHWAYS
HER4 has many characteristics likening it to EGFR/HER1 includ-
ing recruitment of GRB2, SHC, and STAT5. One isoform of HER4
is able to activate the PI3K/AKT pathway (32). HER4 tends to have
low expression in breast and prostate cancers, yet over-expression
is frequently seen in other cancers (e.g.,>50% childhood medullo-
blastomas) (33). In such cases, heterodimerization with HER2
is correlated with malignancy, suggesting increased autocrine or
paracrine loop signaling involving Neuregulin 1 (NRG1) (34).
HER PATHWAY SYNERGY
As referred to above, co-operation between HER receptors has
been observed in oncogenic transformation, both in vitro in
cultured cells and in primary human tumors. For example,
HER3 expression increases HER2-mediated transformation and
tumorigenic growth in NIH3T3 cells (35). Additionally, co-
expression of EGFR/HER1 or HER2 is necessary for NRG-1-
induced transformation of fibroblasts by HER4 (8). The enhanced
proliferative activity of cells expressing multiple HER receptors
are presumably due to the interaction and strength of signal-
ing in HER receptor combinations (36). HER pathway synergy
results in additional autocrine loops driven by co-expression of
multiple HER proteins. Such pathways are closely linked with
tumor progression (8). This synergy of multiple pathways also
provides an “escape route” whereby blocking specific member
of the HER-family results in functional compensation by par-
allel HER pathways. It follows that panHER inhibition may
overcome this shortcoming of single targeted therapies. Table 2
summarizes the regulation mechanisms of the HER signaling
pathways.
SINGLE HER INHIBITORS
Single molecular tyrosine kinase inhibitors (TKIs) are a class
of extensively investigated and developed therapeutics that are
effective alone and in combination with conventional chemother-
apeutics in treating a variety of cancer subtypes. Their mechanism
of action is via inhibition of the single members of the HER-
family culminating in inhibition of downstream signaling (37, 38).
More specifically, TKIs such as erlotinib take effect via reversible
binding to the kinase catalytic domain of EGFR/HER1 preventing
auto-phosphorylation and downstream activation (39). Alterna-
tively, mAbs, such as trastuzumab (40) and cetuximab (41), bind
to the extra-cellular segment of HER-family members leading to
down-regulation.
The success of reversible TKIs has been most marked in patients
harboring an EGFR/HER1 gene mutation that increases TKI sen-
sitivity. Analysis of non-small cell lung cancer (NSCLC) patients
has shown that 70–80% of EGFR/HER1 gene-mutated patients are
responsive to TKIs compared with 10–20% of EGFR/HER1 wild-
type patients (42). In contrast, mAbs mode of action varies from
those of small molecule inhibitors. Accordingly their inhibitory
effects are less dependent upon activation-inducing mutations in
the receptor and even downstream changes. This may explain the
increased therapeutic impact compared to TKIs on patients with
breast and colon cancers (41).
Table 2 | HER signaling regulation.
Regulation mechanism Effect on signaling Mediators and mechanisms
Positive feedback loops Prolong active signaling Hetero-dimers containing HER2 often evade negative regulation. This is due to production
of local EGF-like ligands and angiogenic factors upon activation of receptor
Negative feedback loops Reduction in number of receptors Multiple mechanisms involved: post-translational modifications, compartmentalization,
catalytic inactivation, and steric hindrance. Pre-existing attenuators primarily control
receptor phosphorylation and degradation. For example, density-enhanced phosphatase-1
(DEP-1) dephosphorylates HER1/EGFR
Buffering Up-regulation/down-regulation Heat-shock protein-90 (HSP90) is the most significant protein involved. When bound to
HER2 it acts as a molecular switch – regulating heterodimer formation, catalytic function,
and protein stability
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Shortcomings of single HER inhibitor treatment and strategies to
overcome resistance
Despite successful drug development targeting single HER recep-
tors, patient response has been less than expected, and develop-
ment of resistance has been a major issue. The primary efficacy of
erlotinib and gefitinib in malignancies harboring an EGFR/HER1
activating mutation is well established. However, this efficacy
has shown to be short lived with patients developing secondary
mutations conferring drug resistance. These mutations occur at
a median time of 12 months from commencement of treatment
(42). The EGFR/HER1 T790M resistant mutation involves substi-
tution of threonine 790 with methionine, conferring drug resis-
tance by increasing ATP affinity. Inhibition is initially possible
due to the compromised ATP affinity resulting from EGFR/HER1
mutations, and as such, the T790M mutation culminates in
restoration of wild-type level ATP affinity and a decreased affinity
of TKIs targeting HER receptors. TheT790M mutation is believed
to account for 50% of the resistance to the aforementioned drugs
(43). Other secondary mutations specific to EGFR/HER1 resis-
tance development include D761Y, L747S, and T854A (44). How-
ever, these have only been reported with low frequency and are
not the focus of treatments to overcome resistance. Recently, sev-
eral third-generation, irreversible, selective EGFR inhibitors such
as AZD9291 and CO1686 have shown promise in pre-clinical
studies and provided hope for patients with advanced lung can-
cers that have become resistant to gefitinib or erlotinib. AZD9291
and CO1686 inhibited both the activating (L858R) and resistant
(T790M ) EGFR mutations in cell culture and in animal mod-
els. Conversely, these drugs did not inhibit the wild-type EGFR
that is present in normal skin and gut cells, thereby reducing the
side effects encountered with existing reversible EGFR inhibitors
(45–48). Both compounds are undergoing clinical trials and the
preliminary data have shown partial responses with good tolera-
bility, according to RECIST (response evaluation criteria in solid
tumors), which is a set of published rules that define when cancer
patients improve (“respond”), stay the same (“stable”), or worse
(“progression”) during treatment (49, 50).
In addition to EGFR mutations, MET amplification/over-
expression was also reported as another common EGFR TKI
resistance mechanism in lung cancer. MET amplification was
observed in 21% of patients with acquired resistance to EGFR
TKI (in only 3% of untreated patients) and developed resistance
to gefitinib by driving HER3-dependent activation of PI3K in a
gefitinib-sensitive lung cancer cell line (HCC827) (6, 7), as well as
by activating STAT3 transcription factor directly, through an SH2
domain (51). Targeting MET can enhance EGFR inhibition. EGFR
inhibitors combined with MET tyrosine kinase inhibitors such as
SU11274 and PHA665752 or MET antibody such as DN-30 syn-
ergistically inhibited cell proliferation and promoted apoptosis in
NSCLC (52, 53). A number of MET inhibitors are currently in late
phase clinical trials (54, 55).
Trastuzumab is a monoclonal antibody against HER2 and was
approved for the treatment of HER2-overexpressed metastatic
breast cancer in 1998 (16). However, the majority of patients
who initially responded to trastuzumab showed partial or com-
plete resistance and disease progression in<1 year post treatment
(18). Multiple mechanisms of trastuzumab resistance have been
reported (56) including constitutive activation of downstream
PI3K/AKT signaling through PTEN down-regulation or PIK3CA
hyper-activating mutations, lack of an effective ADCC immune
response as well as increased expression or compensatory signal-
ing through other receptor tyrosine kinases (IGF-IR, EGFR, or
HER3). IGF-IR signaling (17, 57) was demonstrated to contribute
the molecular resistance mechanism to HER2-targeted therapy
via cross-talk between IGFR-IR and HER2, which activated the
PI3K/AKT and Ras/Raf/MAPK signaling cascades. In addition,
trastuzumab only blocks HER2-mediated signaling, but it may
not inhibit signaling mediated from other HER receptors (such as
EGFR/HER3 or EGFR/EGFR) (18). Therefore, inhibiting multiple
HER-family receptors concurrently may be more effective than
trastuzumab-based therapy alone.
Resistance to monoclonal antibody (e.g., cetuximab) or small
molecule receptor inhibitor (gefitinib or dacomitinib) therapy is
most frequently through mutations that result in downstream acti-
vation of the pathway eliminating the opportunity for upstream
blockade of external signaling; for example, cetuximab block-
ade to EGFR/HER1. Karapetis et al. (58) in a randomized trial
of single agent cetuximab vs. best supportive care showed that
a k-ras mutation was a predictor for resistance to cetuximab in
patients. Drugs that target molecules downstream of k-ras (e.g.,
b-raf or MEK inhibitors) are needed to effectively manage these
patients.
Ciardello et al. (59) have shown that HER2 gene amplification
is another mechanism of resistance to EGFR/HER1 targeted ther-
apy. Their study revealed that resistance to cetuximab in metastatic
colorectal cancer “xenopatients” (patient-derived xenografts) was
frequently coupled with HER2 over-expression. When treated with
EGFR and HER2 inhibition, long lasting tumor regression sug-
gested that panHER inhibition will have clinical benefit in such
patients. In addition, blocking of EGFR/HER1 has no impact
on the HER2, HER4, and JAK/STAT pathways (by-pass signal-
ing pathways), in which activation of STAT3 is associated with
tumor growth and malignancy (5, 60). HER2 acts as a STAT3
co-activator for cyclin D1 promoter activation to promote tumor
proliferation (61).
This gives context to the potential benefit of panHER inhibitors.
These irreversible TKIs overcome resistance by binding covalently
to HER receptors, which inhibits tumor growth in cancers, which
are driven by HER heterodimerization and co-expression (62).
panHER INHIBITION APPROACH
In response to the clinical limitations of EGFR/HER1 TKIs, the
role of panHER inhibitors is gaining increased attention. In can-
cers responsive to HER pathway stimulation, as discussed above,
panHER inhibition could provide a means of blocking signal-
ing pathways that are not associated with EGFR/HER1 activating
mutations or gene amplification (hence lower response rates to
reversible TKIs). While panHER inhibitor therapy seems to be
most effective in patients harboring an activating EGFR mutation,
it also shows therapeutic benefit in patients who do not have a
HER activating mutation. Pre-clinical studies have shown inhibi-
tion of wild-type EGFR/HER1 as well as wild-type HER2 using
novel panHER inhibitors (63). Late stage cancers such as lung,
breast, head and neck, gastric, and colorectal, which are associated
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with over-activity of the HER pathways, may all benefit from this
new class of drugs (9).
Effects of a range of panHER inhibitors targeting EGFR/HER1,
HER2, and HER4 have been explored including AC-480 (for-
merly known as BMS 599626), HM781-36B, Canertinib (CI-
1033), Nertinib (HKI272), afatinib (BIBW2992), and dacomitinib
(PF299804). Multi-target TKIs such as lapatinib (an inhibitor
of HER1 and HER2) are already approved and in regular use
in clinical settings, however, resistance has become apparent via
escape route signaling (64). A panHER approach demonstrated
potential to prevent escape route resistance via the JAK/STAT
pathway. AC-480 and HM 781-36B have only just reached or
completed phase I testing, respectively (65, 66). Canertinib and
Nertinib have already entered phase II (67, 68), while dacomi-
tinib and afatinib have been extensively tested in a range of
cancer types and are currently undergoing Phase III studies
(69). Accordingly, dacomitinib and afatinib will be introduced
in the sessions that follow and Tables 3 and 4 include exam-
ples of targeting panHER for cancer therapy. Both compounds
have two attractive features including irreversible binding to the
targeted receptors to extend the efficacy of an agent and over-
come resistance and, in addition, broad inhibition of all cancer-
relevant HER-family homo-dimers and hetero-dimers to poten-
tially improve efficacy and limit alternative signaling from receptor
cross-talk.
REPRESENTATIVE panHER INHIBITOR: DACOMITINIB
Dacomitinib (PF299804) is a second-generation small molecule
tyrosine kinase irreversible panHER inhibitor, which is currently
involved in Phase III trials for NSCLC and Phase II for Head
and Neck cancer (published clinical trials involving dacomitinib
to date are summarized in Table 3). It comprises a structurally
related quinazoline based core scaffold, as well as an electrophilic
motif that covalently binds Cys-797 of EGFR (88). Dacomi-
tinib is potent and highly selective for the EGFR/HER1, HER2,
and HER4 members of the HER (erbB) signaling pathway (73).
It is believed to irreversibly inhibit HER tyrosine kinase activ-
ity through binding at the ATP site and covalent modification
of nucleophilic cysteine residues in the catalytic domains of
HER-family members.
Table 3 | Clinical trials with dacomitinib.
Method Findings Tumor type Reference
2009 Two-arm phase II: efficacy and safety of
dacomitinib in patients (pts) after failure of
chemotherapy and erlotinib (US)
Stable disease was observed in 9/18 pts in Arm A
(adenocarcinoma) and1/2 pts in Arm B (non-adenocarcinoma).
Treatment (Tx)-related adverse events (AEs) were skin and
gastrointestinal disorders
NSCLC (70)
2010 Phase I/II: in Korean pts with k-ras
wild-type adenocarcinoma NSCLC
refractory to chemotherapy and erlotinib
or gefitinib
Dacomitinib (n=30) showed 35% progression-free survival
rate at 4 months, 87% overall survival rate at 6 months, 8%
objective response rate, and 20% clinical benefit rate (partial
response or stable disease ≥24 weeks)
NSCLC (71)
2010 Phase II: efficacy and safety of
dacomitinib as first-line treatment of
patients with advanced NSCLC selected
for activating mutation of EGFR
All evaluable pts with known EGFR-activating mutant NSCLC
(n=14) showed tumor shrinkage. Treatment-related adverse
event were: diarrhea, dermatitis acneiform, and stomatitis
NSCLC (72)
2011 Phase I: 121 patients treated with
dacomitinib either intermittently or daily
continuously
Side effects included diarrhea, rash, fatigue, and nausea.
Dacomitinib can be safely administered up to 45 mg/d
NSCLC, colorectal,
breast, ovarian, biliary,
other
(73)
2012 Phase I: safety and tolerability of
dacomitinib in Japanese pts with
advanced solid tumors (n=13)
Dacomitinib 45 mg/d was defined as the recommended phase
II dose and demonstrated preliminary activity in Japanese pts
with advanced solid tumors
Breast, colon, lung,
and metastatic
neoplasm
(74)
2012 Phase II: observing efficacy of dacomitinib
(n=94) vs. erlotinib (n=94) in patients
after failure of chemotherapy
Dacomitinib showed significantly longer PFS vs. erlotinib in the
overall population (2.86 vs. 1.91 months, p=0.012), with
benefit most notable in k-ras wild-type/EGFR any status, k-ras
wild-type/EGFR wild-type, and EGFR mutants; and higher
objective response rate (17.0 vs. 5.3%, p=0.011). While
toxicity was acceptable; treatment-related side adverse effects
were more frequent in dacomitinib
NSCLC (69)
2013 Phase II: clinical activity of dacomitinib as
first-line treatment in recurrent and/or
metastatic squamous-cell carcinoma of
the head and neck (n=69)
In the response-evaluable patients (n=63), 12.7% pts achieved
a partial response, 57.1% had stable disease, and 14.3% lasting
more than 24 weeks. The median PFS was 12.1 weeks and the
median OS was 34.6 weeks. Most AEs were tolerable
Head and neck (75)
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Table 4 | Clinical trials with afatinib.
Method Findings Tumor type Reference
2008 Phase I: dose-escalation study in
2-week on, 2-week off schedule
Seven patients displayed stable disease lasting more than four
cycles. The PK profile absorption showed oral bioavailability was
moderately fast, and had a half-life suitable for once-daily dosing
Advanced solid
tumors
(76)
2010 Phase I: safety, MTD, and
pharmacokinetics of continuous
once-daily oral administration
Three patients with NSCLC experienced confirmed partial
responses. Seven patients had disease stabilization lasing more
than 6 months. PK was a dose-proportional relationship, with
reduced drug absorption after food intake
Advanced solid
tumors
(77)
2012 Phase I: LUX-lung 4 study in patients
with NSCLC after failure of
chemotherapy/erlotinib/gefitinib
Six patients had tumor size reduction and three achieved durable
stable disease. Peak plasma concentrations were reached 3–4 h
after administration with a half-life of 30–40 h at steady-state
Advanced NSCLC (78)
2013 Phase I: dose-escalation study of
continuous once-daily oral treatment
Five patients had stable disease with a median progression – free
survival of 111 days. PK revealed no deviation from
dose-proportionality and steady-state was reached on day 8
Advanced solid
tumors
(79)
2012 Phase I: continuous oral treatment in
combination with cisplatin/paclitaxel
(n=26) or cisplatin/5-fluorouracil
(n=21)
Disease control was observed in 54 and 29% of patients in
combination with cisplatin/paclitaxel and cisplatin/5-fluorourcial,
respectively. No relevant PK interaction between afatinib and the
chemotherapeutic agents
Advanced solid
tumors
(80)
2013 Phase I: pulsatile 3-day administration
in combination with docetaxel (n=40)
This combination showed 12.5% objective responses and 22.5%
durable stable disease. No drug–drug interactions were observed
between afatinib and docetaxel
Advanced solid
tumors
(81)
2012 Phase II: efficacy of afatinib as first
(n=61) or second line treatment
(n=68) (LUX-lung2)
66% first-line and 57% second line treatment patients showed
objective response after treatment with afatinib daily. The most
common adverse events were diarrhea and rash or acne
Advanced lung
adenocarcinoma with
EGFR mutations
(82)
2012 Exploratory phase II: efficacy of afatinib
in patients with HER2 mutations (n=3)
All three patients with activating HER2 mutations in exon 20
showed objective response even after failure of other EGFR-
and/or HER2-targeted treatment
Advanced lung
adenocarcinoma with
HER2 mutations
(83)
2012 Phase II: efficacy and safety of afatinib
as second or third-line treatment
(n=50)
Afatinib achieved clinical benefit for at least 4 months in a small
number (n=3) of heavily pre-treated unselected patients with
triple-negative breast cancer. The most common treatment-related
adverse events were diarrhea and skin
HER2-negative
metastatic breast
cancer
(84)
2012 Phase IIb/III: afatinib vs. placebo as
third or fourth line treatment in 585
patients (LUX-Lung 1)
Afatinib showed longer progression-free survival (3.3 vs.
1.1 months, p<0.0001) and higher partial response (29 patients
vs. 1 patient, p<0.01). There was no significant difference in
overall survival between afatinib (10.8 months) and placebo group
(12 months, p=0.74)
Advance NSCLC (85)
2012 Phase III: afatinib vs. pemetrexed and
cisplatin as first-line treatment in 345
patients (LUX-Lung 3)
Afatinib showed longer progression-free survival (11.1 vs.
6.9 months, p=0.0004), and higher objective response rate (56
vs. 23%, p<0.0001) than pemetrexed/cisplatin
Advanced lung
adenocarcinoma with
activating EGFR
mutations
(86)
2013 Phase III: safety and efficacy of
first-line afatinib vs.
gemcitabine/cisplatin in Asian patients
with EGFR mutation (LUX-Lung 6)
(n=364)
Afatinib showed significantly prolonged progression-free survival
(11.0 vs. 5.6 months, p<0.0001), higher objective response
(66.9% vs. 23.0%, p<0.0001) and disease control (92.6% vs.
76.2%, p<0.0001) rates, compared with gemcitabine/cisplatin.
Overall survival, based on 43% of events showed p=0.7593.
Advanced lung
adenocarcinoma with
activating EGFR
mutations
(87)
Pre-clinical studies
Dacomitinib is a highly effective inhibitor of EGFR activating
and EGFR T790M acquired resistant mutations as well as the
wild-type HER2, gefitinib-resistant oncogenic HER2 mutation,
and HER2 amplification both in vitro and in vivo in a broad range
of human cancer cell lines including lung cancer, gastric cancer,
biliary tract cancer, breast cancer, head and neck cancer, ovarian
carcinoma, and squamous-cell carcinoma (63, 89–93). Treatment
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with dacomitinib reduced phosphorylation of HER-family mem-
bers (EGFR, HER2, and HER4) and downstream AKT and Erk
pathways, as well as induced apoptosis and caused G0/G1 arrest
(91, 92). Furthermore, excellent pharmacodynamic effects (such
as high bioavailability, long half-life, and large volume of distribu-
tion) with this compound were observed across species including
rats, monkeys, and dogs (93). Despite apparent success in treating
tumors with an EGFR/HER1 T790M resistant mutation, pre-
clinical studies (88) using cell lines with EGFR T790M showed
that dacomitinib resistance can develop both in vitro and using
a xenograft model in vivo by EGFR/HER1 T790M amplification.
The activation of IL-6R/JAK1/STAT3 signaling has been identi-
fied as a mechanism of de novo resistance to irreversible panHER
inhibitors in NSCLC with T790M resistant mutation (94).
Phase I studies
Three Phase I studies in patients with advanced malignant solid
tumors in United States, Japan, and South Korea indicated that
dacomitinib has attractive pharmacokinetics and metabolism
including great bioavailability, long half-life (59–85 h with dosing
ranging from 30 to 60 mg), large volume of distribution (2,610 L
with the dosing of 45 mg), and low clearance (23.7–32 L/h across
the dosing of 15–45 mg) (71, 73, 74). These studies suggested the
maximum tolerated dose (MTD) was 45 mg/d, and both contin-
uous and intermittent treatment schedules were well-tolerated.
However, this has revealed that concentrations, which are clinically
achievable may not allow maximum inhibition of cells harboring
the T790M resistant mutation. Treatment-related adverse effects
(diarrhea, acne, and rash) associated with EGFR/HER1 block-
ing TKIs were more common in dacomitinib compared with
erlotinib (95).
Phase II studies
In two subsequent phase II trials in NSCLC as a third-line
treatment, dacomitinib was well-tolerated and showed encour-
aging activity in patients after failure of prior chemotherapy
and erlotinib or gefitinib treatment (70, 71). A randomized
Phase II trial of 188 patients with advanced NSCLC demon-
strated a significant improvement of progression-free survival
(PFS) in patients receiving dacomitinib (2.86 months) compared
to erlotinib (1.91 months) (69). In two Phase II studies of dacomi-
tinib as a first-line therapy, dacomitinib demonstrated clinical
benefits in patients with recurrent and/or metastatic squamous-
cell carcinoma of the head and neck (RM-SCCHN) and advanced
NSCLC (72, 75).
Dacomitinib, currently under phase III studies (JBR-26 and
NCT01360554), appears to be an example of how the panHER
approach to targeted therapy may hold promise for improving
targeted treatment outcomes. Activity demonstrated in NSCLC
may also have an application within other cancer types with pos-
itive HER-family expression such as other epithelial cancers (96)
and sarcoma (97).
REPRESENTATIVE panHER INHIBITOR: AFATINIB
Afatinib, an aniline–quinazoline derivative with a functional
Michael acceptor group, is designed to covalently bind the cat-
alytic domains of EGFR (Cys-797), HER2 (Cys805), and HER4
(Cys803) and irreversibly block enzymatically active HER-family
members (98).
Pre-clinical studies
In cell-free in vitro kinase assays, afatinib potently inhibited wild-
type EGFR (EC50= 0.5 nM), HER2 (14 nM), and HER4 (1 nM),
as well as oncogenic L858R activating mutant EGFR (0.4 nM) and
L858R-T790M resistant mutant EGFR (10 nM) (98, 99). Afatinib
inhibited auto-phosphorylation of HER members and prolifera-
tion in cancer cell lines representing different mutational status
of EGFR and HER2, including wild-type EGFR (A431), activat-
ing mutant EGFR (PC-9 and H3255, EC50= 0.4 and 0.5 nM,
respectively), L858R-T790M mutant EGFR (NCI-H1975), L858R-
T854A mutant EGFR (transfected 293T), and HER2 amplification
(BT474) with EC50 below 100 nM, whereas NCI-H1975, T854A
transfected 293T, and BT474 were resistant to erlotinib and/or
gefitinib (98, 100). Furthermore, afatinib induced tumor regres-
sion in a broad spectrum of xenograft models carrying epidermoid
carcinoma A431 with wild-type EGFR, gastric cancer NCI-N87
with HER2 over-expression, lung cancer NCI-H1975 with L858R-
T790M mutant EGFR, and adenosquamous lung tumor with
HER2YVMA mutation, with superior activity over erlotinib (99,
101). In a panel of seven human pancreatic tumor cell lines, afa-
tinib indicated greater efficacy in antiproliferation and signaling
blockage (phosphorylation of EGFR, MAPK, and AKT) (102).
In vivo, daily administration of 15 mg/kg afatinib showed potent
antitumor activity in the BxPC-3 human pancreatic xenograft
model (102).
Clinical trials using Afatinib are listed in Table 4.
Phase I studies
Several Phase I dose-escalation studies with afatinib indicated
that afatinib is well-tolerated (76–79, 103). The recommended
dose in 2-week on, 2-week off schedule is 70 mg/d (76), while
in once-daily oral treatment is 40–50 mg/d in advanced solid
tumors and in advanced NSCLC after failure of chemother-
apy/erlotinib/gefitinib (LUX-Lung4) (77–79). The most frequent
treatment-related adverse events were diarrhea, mucosal inflam-
mation, and skin rash. A pharmacokinetic study in healthy male
volunteers with afatinib showed the main route of excretion is via
feces, and it undergoes minimal metabolism (103).
Phase II studies
LUX-Lung 2, a single-arm phase II study in 129 patients with lung
adenocarcinoma containing activating EGFR mutations within
exons 18-21, showed antitumor activity after treatment as first or
second line with afatinib daily 40 or 50 mg (82). Afatinib was more
effective (objective response: 66%) in patients with the common
EGFR mutations (deletion 19 and L858R) compared to patients
with less common mutations (39%) (82). In addition, afatinib
indicated therapeutic activity in three patients with lung adeno-
carcinoma and a non-smoking history, whose tumors exhibited
activating HER2 mutation in exon 20 (83). However, afatinib had
limited activity in HER2-negative breast cancer (84). None of the
fifty patients achieved an objective response, while three patients
with triple-negative metastatic breast cancer had stable disease
for more than four treatment courses. This indicated that further
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examination of afatinib in patients should select population with
EGFR/HER2 mutations or HER receptor/ligand over-expression
or activation to increase the likelihood of a meaningful clinical
benefit.
Phase III studies
LUX-Lung 1 was a randomized, double-blind phase IIb/III study
comparing afatinib with placebo in 585 NSCLC patients after
failure of chemotherapy/erlotinib/gefitinib (85). Afatinib failed
to show a difference between groups at its primary endpoint
and overall survival, although the PFS findings were promising.
One of the potential reasons is that the number of patients with
EGFR mutations was unknown, since EGFR mutation status was
not required for study entry. Accordingly, LUX-Lung 3 examined
the efficacy of afatinib compared with pemetrexed and cisplatin
as first-line treatment for patients with advanced lung adeno-
carcinoma harboring EGFR-activating mutations. Encouragingly,
afatinib led to a prolonged PFS, more significantly with common
Del19 and L858R mutations (86, 87).
In July 2013, afatinib was approved for the first-line treatment
of patients with metastatic NSCLC with EGFR exon 19 deletions
or exon 21 (L858R) substitution mutations by the US Food and
Drug Administration (104).
panHER COMBINATION THERAPY
Combination therapy involving panHER inhibitors is also under
investigation. This varies from combinations of targeted therapies
with either radiation or chemotherapy or combinations of targeted
therapies directed against different aspects of the EGFR pathway.
Following radiotherapy, tissue recovery is associated with
increased generation of HER ligands to promote the survival
and cell proliferation that HER signaling provides. One poten-
tial outcome of this tissue repair event is tumor recurrence in
patients with high HER expression. It follows biologically that
blocking HER pathways simultaneously may impair this process
and thus enhance radiation effectiveness (105). Torres et al. (106)
showed that panHER inhibitor AC-480 increased tumor growth
delay (enhancement factor= 1.94) when used in combination
with radiotherapy in head and neck squamous-cell carcinoma
in mice.
panHER inhibitors in combination with chemotherapy have
successfully showed synergistic results in both pre-clinical studies
and clinical trials. Combination therapy in NSCLC cells har-
boring a T790M mutation both in vitro and in vivo showed
(107) that gefitinib (EGFR/HER1 TKI) used in combination with
antimetabolites, either fluorouracil (5FU) or pemetrexed, had an
antagonistic growth inhibitory effect in vitro. In contrast, afatinib
both in vitro and in vivo was synergistic with these drugs. In
two phase I studies of afatinib combination with chemotherapy,
the MTD for afatinib was 20 mg with cisplatin/paclitaxel, 30 mg
with cisplatin/5-fluorouracil, and 90 mg for 3 days after docetaxel
in advanced solid tumors (80, 81). Both studies showed antitu-
mor activities with a manageable adverse-event profile. CI-1033
is another panHER inhibitor with promising lab data showing
it synergizes with cisplatin in vitro (108). This is believed to
be because cisplatin inhibits key genes in cell survival when the
EGFR pathway is blocked simultaneously. CI-1033 has undergone
a phase I trial in combination with docetaxel in advanced solid
tumor patients. It appeared to be safe with acceptable side effects
following an intermittent administration schedule (109). CI-1033
has also been examined in combination with paclitaxel and carbo-
platin in advanced NSCLC patients (110). Phase I studies showed it
was well-tolerated as well as having possible synergistic antitumor
trends, which await confirmation in phase II studies. Lapatinib
(HER1/HER2 TKI) has been approved by the FDA for routine
clinical use in combination with capecitabine (prodrug of 5FU).
This is on the basis of phase III studies showing improved PFS in
HER2 positive breast cancer (12.0 weeks in combination therapy
vs. 8.4 weeks in lapatinib alone) (111).
Another approach to target the HER-family is through concur-
rent treatment with new bispecific antibodies such as MM-111
and an HER2 antibody or small molecular inhibitor. MM-111
targets the HER2/HER3 heterodimer with specificity and avid-
ity by docking onto HER2 and subsequently binding to HER3
and blocking Heregulin-induced activation of HER3, therefore,
it is more effective at inhibiting HER3 activation than a HER2
or HER3 monoclonal antibody (trastuzumab and pertuzumab)
and TKI (lapatinib) (112). In addition, combining MM-111 with
other HER2-targeted agents (trastuzumab and/or lapatinib) and
chemotherapy (such as paclitaxel) synergistically inhibit tumor
cell growth and prevent the development of HER3-driven drug
resistance in gastric and breast cancer cells and xenografts (113–
115). Currently, a Phase II clinical trial combining MM-111 with
paclitaxel and trastuzumab is being investigate (116).
The development of bispecific antibodies, along with the third-
generation irreversible small molecular inhibitors, have improved
the efficacy to target HER-family, even though they clearly dif-
fer in their mode of action at target level: for example, MM-111,
consisting of fully human anti-HER2 and anti-HER3 single chain
antibody moieties linked by modified human serum albumin, tar-
gets the extra-cellular domain of HER2/HER3 heterodimer and
promotes the formation of inactive trimetric complexes. In com-
parison, the third-generation EGFR TKIs (AZD9291 and CO1686)
act on the intracellular ATP binding domain and irreversibly
inhibit both the activating and resistant EGFR mutations (45,
48, 112). Based on our current knowledge, there is no apparent
distinction between antibodies and TKIs regarding HER-family
targeting effects. However, their differences could be exploited
in certain clinical situations. For example, patients with activat-
ing and/or resistant EGFR mutations should be considered for
the use of third-generation EGFR TKIs, whereas patients with
over-expression of HER2/HER3 should be treated by bispecific
antibody MM-111. Generally, TKIs as small molecules are able
to penetrate the blood-brain barrier, indicating that these agents
may be therapeutic in patients with primary or metastatic cen-
tral nervous system disease (117). By contrast more clarity about
the potential for ADCC to have a role in antibody-mediated
antitumor activity may encourage development of this as the
favored therapeutic approach. Especially FcγR genotype may be
a predictor of efficacy (118). Indeed rather than focusing on
identifying which approach is optimal, it is possible that inhi-
bition of multiple sites of HER receptor activation using both
antibody and TKI will prove to be the best way forward. A
recent example showed an enhanced antitumor activity when
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HER-antibody trastuzumab was combined with an EGFR TKI
gefitinib or erlotinib (117).
SOFT TISSUE SARCOMAS AS A NOVEL TARGET
EGFR/HER1 is frequently overexpressed in soft tissue sarcoma,
with 78% of patient tissue samples showing positive EGFR/HER1
expression in a study by Yang et al. (119). Early data suggest that
blocking EGFR/HER1 by its specific inhibitor may have activity
in sarcomas through tyrosine kinase signaling inhibition (14).
However, such blockade has no impact on the HER2, HER4,
and JAK/STAT pathways, in which activation of STAT3 is associ-
ated with tumor growth (120). This problem with single receptor
blockage is also confirmed in clinical studies (121), showing that
erlotinib was not active in malignant peripheral nerve sheath
tumors (MPNST), which are relatively resistant to chemother-
apy. Similarly, cetuximab has minimal activity in EGFR positive
advanced sarcoma (122).
Recently, a phase II trial in osteosarcoma patients with HER2
over-expression showed that blocking HER2 using trastuzumab in
combination with cytotoxic chemotherapy had no clinical bene-
fit (123). The promising data discussed earlier regarding panHER
combination therapy could justify a trial in such disease groups to
overcome the failure of single targeting.
CONCLUSION
Targeted therapy against the HER-family individual members or
panHER-family has shown potential to improve prognosis in
sensitive patients in some tumor types. One mechanism of resis-
tance to EGFR/HER1 therapies is HER2, 3, 4, and JAK/STAT
by-pass signaling. Pre-clinical studies and clinical trials of panHER
inhibitors show promising results, and the potential to improve
patient outcomes in NSCLC and head and neck cancers. In some
cancer patients, the panHER inhibition approach met resistance
from HER-independent JAK/STAT by-pass signaling. The use of
STAT3 blockage in combination with panHER inhibition in can-
cers including epithelial cancers and sarcoma, with HER-family
hyper-activation and resistance to panHER inhibitor, is a new
direction to explore and has potential in clinical cancer therapy
in the future.
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